Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy

W. Y. Kao, Y. Y. Chiou, H. H. Hung, C. W. Su, Y. H. Chou, J. C. Wu, T. I. Huo, Y. H. Huang, W. C. Wu, H. C. Lin, S. D. Lee

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Aims: To evaluate the clinical inference of serum alpha-fetoprotein (AFP) response in hepatocellular carcinoma (HCC) patients undergoing percutaneous radiofrequency ablation (RFA). Materials and methods: Three hundred and thirteen previously untreated HCC patients were enrolled in the study. The optimal AFP response was defined as >20% decrease from baseline after 1 month of RFA for those with a baseline AFP level of ≥100 ng/ml. The impact of AFP response on prognosis was analysed and prognostic factors were assessed. Results: After a median follow-up of 26.7 ± 19.1 months, 49 patients died and 264 patients were alive. The cumulative 5 year survival rates were 75.3 and 57.4% in patients with an initial AFP of <100 ng/ml and ≥100 ng/ml, respectively (p = 0.003). In the 58 patients with a baseline AFP of ≥100 ng/ml and initial completed tumour necrosis after RFA, the cumulative 5 year survival rates were 62.4 and 25.7% in optimal and non-optimal AFP responders, respectively (p = 0.001). By multivariate analysis, the prothrombin time international normalized ratio >1.1 (p = 0.009), non-optimal AFP response (p = 0.023), and creatinine >1.5 mg/dl (p = 0.021) were independent risk factors predictive of poor overall survival. Besides, the cumulative 5 year recurrence rates were 83.4 and 100% in optimal and non-optimal AFP responders, respectively (p < 0.001). Multivariate analysis demonstrated platelet count ≤105/mm 3 (p = 0.048), tumour size >2 cm (p = 0.027), and non-optimal AFP response (p < 0.001) were independent risk factors associated with tumour recurrence after RFA. Conclusions: Serum AFP response may be a useful marker for predicting prognosis in HCC patients undergoing RFA.

Original languageEnglish
Pages (from-to)429-436
Number of pages8
JournalClinical Radiology
Volume67
Issue number5
DOIs
Publication statusPublished - Jan 1 2012
Externally publishedYes

Fingerprint

alpha-Fetoproteins
Hepatocellular Carcinoma
Serum
Therapeutics
Recurrence
Creatinine
Survival Rate
Survival

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. / Kao, W. Y.; Chiou, Y. Y.; Hung, H. H.; Su, C. W.; Chou, Y. H.; Wu, J. C.; Huo, T. I.; Huang, Y. H.; Wu, W. C.; Lin, H. C.; Lee, S. D.

In: Clinical Radiology, Vol. 67, No. 5, 01.01.2012, p. 429-436.

Research output: Contribution to journalArticle

Kao, WY, Chiou, YY, Hung, HH, Su, CW, Chou, YH, Wu, JC, Huo, TI, Huang, YH, Wu, WC, Lin, HC & Lee, SD 2012, 'Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy', Clinical Radiology, vol. 67, no. 5, pp. 429-436. https://doi.org/10.1016/j.crad.2011.10.009
Kao, W. Y. ; Chiou, Y. Y. ; Hung, H. H. ; Su, C. W. ; Chou, Y. H. ; Wu, J. C. ; Huo, T. I. ; Huang, Y. H. ; Wu, W. C. ; Lin, H. C. ; Lee, S. D. / Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. In: Clinical Radiology. 2012 ; Vol. 67, No. 5. pp. 429-436.
@article{9b7ff7a67ff34a74ae10e9c730738410,
title = "Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy",
abstract = "Aims: To evaluate the clinical inference of serum alpha-fetoprotein (AFP) response in hepatocellular carcinoma (HCC) patients undergoing percutaneous radiofrequency ablation (RFA). Materials and methods: Three hundred and thirteen previously untreated HCC patients were enrolled in the study. The optimal AFP response was defined as >20{\%} decrease from baseline after 1 month of RFA for those with a baseline AFP level of ≥100 ng/ml. The impact of AFP response on prognosis was analysed and prognostic factors were assessed. Results: After a median follow-up of 26.7 ± 19.1 months, 49 patients died and 264 patients were alive. The cumulative 5 year survival rates were 75.3 and 57.4{\%} in patients with an initial AFP of <100 ng/ml and ≥100 ng/ml, respectively (p = 0.003). In the 58 patients with a baseline AFP of ≥100 ng/ml and initial completed tumour necrosis after RFA, the cumulative 5 year survival rates were 62.4 and 25.7{\%} in optimal and non-optimal AFP responders, respectively (p = 0.001). By multivariate analysis, the prothrombin time international normalized ratio >1.1 (p = 0.009), non-optimal AFP response (p = 0.023), and creatinine >1.5 mg/dl (p = 0.021) were independent risk factors predictive of poor overall survival. Besides, the cumulative 5 year recurrence rates were 83.4 and 100{\%} in optimal and non-optimal AFP responders, respectively (p < 0.001). Multivariate analysis demonstrated platelet count ≤105/mm 3 (p = 0.048), tumour size >2 cm (p = 0.027), and non-optimal AFP response (p < 0.001) were independent risk factors associated with tumour recurrence after RFA. Conclusions: Serum AFP response may be a useful marker for predicting prognosis in HCC patients undergoing RFA.",
author = "Kao, {W. Y.} and Chiou, {Y. Y.} and Hung, {H. H.} and Su, {C. W.} and Chou, {Y. H.} and Wu, {J. C.} and Huo, {T. I.} and Huang, {Y. H.} and Wu, {W. C.} and Lin, {H. C.} and Lee, {S. D.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.crad.2011.10.009",
language = "English",
volume = "67",
pages = "429--436",
journal = "Clinical Radiology",
issn = "0009-9260",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy

AU - Kao, W. Y.

AU - Chiou, Y. Y.

AU - Hung, H. H.

AU - Su, C. W.

AU - Chou, Y. H.

AU - Wu, J. C.

AU - Huo, T. I.

AU - Huang, Y. H.

AU - Wu, W. C.

AU - Lin, H. C.

AU - Lee, S. D.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Aims: To evaluate the clinical inference of serum alpha-fetoprotein (AFP) response in hepatocellular carcinoma (HCC) patients undergoing percutaneous radiofrequency ablation (RFA). Materials and methods: Three hundred and thirteen previously untreated HCC patients were enrolled in the study. The optimal AFP response was defined as >20% decrease from baseline after 1 month of RFA for those with a baseline AFP level of ≥100 ng/ml. The impact of AFP response on prognosis was analysed and prognostic factors were assessed. Results: After a median follow-up of 26.7 ± 19.1 months, 49 patients died and 264 patients were alive. The cumulative 5 year survival rates were 75.3 and 57.4% in patients with an initial AFP of <100 ng/ml and ≥100 ng/ml, respectively (p = 0.003). In the 58 patients with a baseline AFP of ≥100 ng/ml and initial completed tumour necrosis after RFA, the cumulative 5 year survival rates were 62.4 and 25.7% in optimal and non-optimal AFP responders, respectively (p = 0.001). By multivariate analysis, the prothrombin time international normalized ratio >1.1 (p = 0.009), non-optimal AFP response (p = 0.023), and creatinine >1.5 mg/dl (p = 0.021) were independent risk factors predictive of poor overall survival. Besides, the cumulative 5 year recurrence rates were 83.4 and 100% in optimal and non-optimal AFP responders, respectively (p < 0.001). Multivariate analysis demonstrated platelet count ≤105/mm 3 (p = 0.048), tumour size >2 cm (p = 0.027), and non-optimal AFP response (p < 0.001) were independent risk factors associated with tumour recurrence after RFA. Conclusions: Serum AFP response may be a useful marker for predicting prognosis in HCC patients undergoing RFA.

AB - Aims: To evaluate the clinical inference of serum alpha-fetoprotein (AFP) response in hepatocellular carcinoma (HCC) patients undergoing percutaneous radiofrequency ablation (RFA). Materials and methods: Three hundred and thirteen previously untreated HCC patients were enrolled in the study. The optimal AFP response was defined as >20% decrease from baseline after 1 month of RFA for those with a baseline AFP level of ≥100 ng/ml. The impact of AFP response on prognosis was analysed and prognostic factors were assessed. Results: After a median follow-up of 26.7 ± 19.1 months, 49 patients died and 264 patients were alive. The cumulative 5 year survival rates were 75.3 and 57.4% in patients with an initial AFP of <100 ng/ml and ≥100 ng/ml, respectively (p = 0.003). In the 58 patients with a baseline AFP of ≥100 ng/ml and initial completed tumour necrosis after RFA, the cumulative 5 year survival rates were 62.4 and 25.7% in optimal and non-optimal AFP responders, respectively (p = 0.001). By multivariate analysis, the prothrombin time international normalized ratio >1.1 (p = 0.009), non-optimal AFP response (p = 0.023), and creatinine >1.5 mg/dl (p = 0.021) were independent risk factors predictive of poor overall survival. Besides, the cumulative 5 year recurrence rates were 83.4 and 100% in optimal and non-optimal AFP responders, respectively (p < 0.001). Multivariate analysis demonstrated platelet count ≤105/mm 3 (p = 0.048), tumour size >2 cm (p = 0.027), and non-optimal AFP response (p < 0.001) were independent risk factors associated with tumour recurrence after RFA. Conclusions: Serum AFP response may be a useful marker for predicting prognosis in HCC patients undergoing RFA.

UR - http://www.scopus.com/inward/record.url?scp=84859425495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859425495&partnerID=8YFLogxK

U2 - 10.1016/j.crad.2011.10.009

DO - 10.1016/j.crad.2011.10.009

M3 - Article

AN - SCOPUS:84859425495

VL - 67

SP - 429

EP - 436

JO - Clinical Radiology

JF - Clinical Radiology

SN - 0009-9260

IS - 5

ER -